A systematic review showed that tumor markers, like chromogranin A, pancreatic polypeptide (PP), or glucagon, are not helpful in diagnosing NF-PanNETs in MEN1 patients due to their low sensitivity and specificity [53]. The gene discussed is PPY; the disease is neoplasm.